Genmab A/S (OTCMKTS:GNMSF – Get Rating)’s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $392.30 and traded as high as $422.25. Genmab A/S shares last traded at $422.25, with a volume of 276 shares trading hands.
Genmab A/S Stock Performance
The stock has a market cap of $27.60 billion, a PE ratio of 38.01 and a beta of 0.90. The company’s 50 day simple moving average is $392.30 and its 200 day simple moving average is $403.92.
Genmab A/S (OTCMKTS:GNMSF – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. The company reported $1.21 EPS for the quarter. The company had revenue of $717.54 million during the quarter. Genmab A/S had a net margin of 34.34% and a return on equity of 19.67%.
Genmab A/S Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
- Get a free copy of the StockNews.com research report on Genmab A/S (GNMSF)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.